Merck (MRK) Ticks Higher Following Positive Odanacatib Phase III News
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $145.60 +2.26%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +0.1%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +0.1%
Join SI Premium – FREE
Merck & Co. (NYSE: MRK) shares are ticking higher in late trading Wednesday, following positive news for its investigational cathepsin K (cat-K) inhibitor, odanacatib.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck eye drug matches anti-VEGF in DME trial with safety caveats
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic
- Johnson & Johnson releases 2-year psoriasis drug data at dermatology meeting
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
